Relationship of Grade, Intrinsic Subtype and Clinical Response to Neoadjuvant Chemotherapy In Breast Cancer

Adliah Purnawaty, William Hamdani, Idham Djaya Ganda


Neoadjuvant chemotherapy has become the standard treatment strategy for locally advanced breast cancer. Currently, neoadjuvant chemotherapy was applied empirically; there are no conventional biomarkers that allow for predicting clinical response and benefit from a particular chemotherapy regimen. Studies mention that grade and intrinsic subtypes are predictors for clinical response to chemotherapy. Purpose of this study were to know the relationship of grade, intrinsic subtype, and clinical response to neoadjuvant chemotherapy in breast cancer. Cross-sectional studies by examining breast cancer patients who underwent chemotherapy in Wahidin Sudirohusodo,  a top referral hospital with 913 bed in Makassar Indonesia, from January 2015 to December 2016. Results: During the periods, neoadjuvant chemotherapy have been conducted to 119 breast cancer patients. In the bivariate analysis, we found that grade significantly associated with chemotherapy response obtained p-value = 0.002 (p < 0.005). Clinical response to neoadjuvant chemotherapy based on subtypes was Luminal A 55.2%, Luminal B 61.2 %, Her2 80%, Triple Negative 87.5%. Association of subtype and chemotherapy response was also significant with p-value = 0.056. Conclusion: histopathological grading and Intrinsic subtype were associated with anthracycline-based neoadjuvant chemotherapy response on breast cancer.  


Breast Cancer; Chemotherapy; Clinical Response; Grade; Subtype.

Full Text:



. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61(2):69-90.

. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975–2008. Bethesda, MD: National Cancer Institute; 2011. Also available online Last accessed December. 2011;1.

. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer biology & medicine. 2014;11(2):101-15.

. Wahidin M, Noviani R, Hermawan S, Andriani V, Ardian A, Djarir H. Population-based cancer registration in Indonesia. Asian Pacific Journal of Cancer Prevention. 2012;13(4):1709-10.

. Thomssen C, Scharl A, Harbeck N, Committee AB. AGO recommendations for diagnosis and treatment of patients with primary and metastatic breast cancer. Update 2011. Breast Care. 2011;6(4):299-313.

. Aebi S, Davidson T, Gruber G, Cardoso F, Group EGW. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of oncology. 2011;22(suppl 6):vi12-vi24.

. Connolly RM, Stearns V. Current approaches for neoadjuvant chemotherapy in breast cancer. European journal of pharmacology. 2013;717(1):58-66.

. Page R, Takimoto C. Principles of chemotherapy, Cancer management: a multidisciplinary approach. 2013.

. Gong C, Yao H, Liu Q, Chen J, Shi J, Su F, et al. Markers of tumor-initiating cells predict chemoresistance in breast cancer. PloS one. 2010;5(12):e15630.

. Skeel RT, Khleif SN. Handbook of cancer chemotherapy: Lippincott Williams & Wilkins; 2011.

. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. Journal of Clinical Oncology. 2006;24(12):1940-9.

. Prihantono P, Hatta M, Binekada C, Sampepajung D, Haryasena H, Nelwan B, et al. Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. Journal of Oncology. 2017;2017.

. Prihantono P, Mochammad Hatta, Andi Asadul Islam. Correlation of BCL-2 and ERα mRNA Expression with the Clinical Chemotherapeutic Response in Breast Cancer. Journal of Medical Sciences(Faisalabad) 2017;17(1):7.

. Christian Binekada DS, Prihantono, Berti Nelwan. Relationship of P-glycoprotein (Pgp) Expression and Estrogen Receptor (ER) Expression in Invasive Ductal Carcinoma of Breast Cancer. International Journal of Sciences:Basic and Applied Research (IJSBAR). 2017;32(1):6.

. Prihantono P, Hatta M, Sampepajung D, Islam AA, Rahardjoe W, Hamdani W, et al. Association of Dual Specific Phosphatase 4 (DUSP4) Expression and Anthracycline-Based Neoadjuvant Chemotherapy Response in Breast Cance. International Journal of Sciences: Basic and Applied Research (IJSBAR). 2017;31(3):125-33.

. Engstrøm MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et al. Molecular subtypes, histopathological grade and survival in a historical cohort of breast cancer patients. Breast cancer research and treatment. 2013;140(3):463-73.

. Lv M, Li B, Li Y, Mao X, Yao F, Jin F. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pacific journal of cancer prevention: APJCP. 2010;12(9):2411-7.

. Prihantono P, Haryasena H, Sampepajung D. Breast Cancer Chemotherapy Response in Wahidin Sudirohusodo Hospital, Makassar. Nusantara Medical Science Journal. 2016(1):1-9.

. Goldhirsch A, Wood W, Coates A, Gelber R, Thürlimann B, Senn H-J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology. 2011:mdr304.

. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiology Biomarkers & Prevention. 2012;21(10):1848-55.

. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research. 2005;11(16):5678-85.


  • There are currently no refbacks.





About IJSBAR | Privacy PolicyTerms & Conditions | Contact Us | DisclaimerFAQs 

IJSBAR is published by (GSSRR).